Florence Wong
#94,979
Most Influential Person Now
Canadian hepatologist
Florence Wong's AcademicInfluence.com Rankings
Florence Wongphilosophy Degrees
Philosophy
#7565
World Rank
#10798
Historical Rank
Logic
#4614
World Rank
#5928
Historical Rank
Download Badge
Philosophy
Florence Wong's Degrees
- PhD Biomedical Sciences University of British Columbia
Why Is Florence Wong Influential?
(Suggest an Edit or Addition)According to Wikipedia, Florence Wong is a Canadian hepatologist and scientist best known for her research into the development and management of complications of cirrhosis. She is a professor of gastroenterology at the University of Toronto and a physician in the Division of Gastroenterology and Hepatology at the University Health Network.
Florence Wong's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis (2007) (947)
- The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club (2003) (826)
- Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. (2015) (672)
- Cirrhotic cardiomyopathy (2009) (569)
- Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. (2007) (476)
- A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. (2005) (451)
- Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension (1995) (431)
- Survival in infection‐related acute‐on‐chronic liver failure is defined by extrahepatic organ failures (2014) (411)
- Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B (2000) (411)
- The North American Study for the Treatment of Refractory Ascites. (2003) (391)
- Hyponatremia in cirrhosis: Results of a patient population survey (2006) (388)
- Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club (2005) (379)
- Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis (2011) (370)
- Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome (2004) (353)
- Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end‐stage liver disease (NACSELD) experience (2012) (329)
- A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial (2003) (296)
- The cardiac response to exercise in cirrhosis (2001) (270)
- Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. (2019) (237)
- Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites (1995) (230)
- Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites (2015) (223)
- New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. (2013) (217)
- Acute kidney injury in decompensated cirrhosis (2012) (208)
- Simultaneous Liver–Kidney Transplantation: Evaluation to Decision Making (2007) (199)
- Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial (2008) (196)
- Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. (2016) (181)
- The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis (2016) (181)
- Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis (2010) (169)
- The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt (2009) (166)
- Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort (2020) (161)
- Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group (2012) (159)
- NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis (2018) (158)
- Portopulmonary hypertension in decompensated cirrhosis with refractory ascites (2003) (156)
- Needle tract seeding after radiofrequency ablation of hepatic tumors. (2005) (150)
- The hyperdynamic circulation in cirrhosis: an overview. (2001) (149)
- Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B (2004) (149)
- Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. (1999) (146)
- Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity (2011) (118)
- The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. (1997) (109)
- Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. (2021) (107)
- Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. (2015) (103)
- Diagnosis, evaluation, and management of ascites and hepatorenal syndrome. (2021) (98)
- Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation (2015) (98)
- Recent advances in our understanding of hepatorenal syndrome (2012) (95)
- Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? (2001) (95)
- Hepatorenal syndrome (2018) (92)
- New challenge of hepatorenal syndrome: Prevention and treatment (2001) (90)
- Central blood volume in cirrhosis: Measurement with radionuclide angiography (1993) (89)
- Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures (2017) (87)
- Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. (1997) (85)
- Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. (2010) (82)
- Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases (2021) (81)
- Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment (2009) (80)
- Bacterial infections in end-stage liver disease: current challenges and future directions (2012) (80)
- Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites (2001) (77)
- Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time? (2018) (75)
- Drug Insight: the role of albumin in the management of chronic liver disease (2007) (73)
- Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort (2017) (73)
- Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis (2019) (72)
- Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies (2017) (66)
- Long‐term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion (2015) (66)
- A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis (2017) (65)
- Hip pain and heart failure: the missing link. (2013) (65)
- Beta‐blockers in cirrhosis: Friend and foe? (2010) (65)
- Quality of life in refractory ascites: Transjugular intrahepatic portal‐systemic shunting versus medical therapy (2005) (64)
- Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries (2021) (62)
- Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. (2016) (59)
- Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. (1999) (59)
- High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease (2015) (58)
- Acute kidney injury in liver cirrhosis: new definition and application (2016) (57)
- Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes (2017) (55)
- Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. (1995) (55)
- Ramipril-associated hepatotoxicity. (2003) (55)
- Renal response to a saline load in well‐compensated alcoholic cirrhosis (1994) (55)
- Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. (1993) (53)
- Management of ascites in cirrhosis (2012) (51)
- Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. (2019) (51)
- Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. (2020) (49)
- Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis (2000) (45)
- Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. (1993) (45)
- Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study (2010) (45)
- Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome (2007) (45)
- The Laennec grading system for assessment of hepatic fibrosis Validation by correlation with wedged hepatic vein pressure and clinical features (2000) (44)
- Impact of Chronic Kidney Disease on Outcomes in Cirrhosis (2019) (43)
- Acute-on-Chronic Liver Failure Clinical Guidelines (2022) (42)
- Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute on Chronic Liver Failure and Death in Patients With Cirrhosis. (2020) (41)
- The use of TIPS in chronic liver disease. (2006) (40)
- The evolving concept of acute kidney injury in patients with cirrhosis (2015) (40)
- Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience (2019) (39)
- The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis (2018) (39)
- The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. (2002) (39)
- Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation (2018) (39)
- Protecting the Kidney in Liver Transplant Candidates: Practice‐Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice (2016) (38)
- Is there a cirrhotic cardiomyopathy? (2000) (38)
- The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. (1998) (37)
- Transjugular intrahepatic portosystemic shunt for refractory ascites: Tipping the sodium balance (1995) (37)
- 219 Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B (2003) (35)
- 732 Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia (2006) (35)
- The Effects of Hypothyroidism on Liver Status of Cirrhotic Patients (2000) (34)
- Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome (2017) (34)
- Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort (2019) (33)
- New diagnostic criteria and management of acute kidney injury. (2017) (33)
- Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development (2013) (32)
- Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. (2019) (31)
- Pathophysiology of sodium retention and ascites formation in cirrhosis: role of atrial natriuretic factor. (1994) (31)
- Pathways of hepatic and renal damage through non‐classical activation of the renin‐angiotensin system in chronic liver disease (2020) (31)
- A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be. (2015) (30)
- Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. (2006) (30)
- Model for End‐Stage Liver Disease‐Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease (2020) (28)
- Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. (2007) (28)
- Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well‐compensated cirrhosis (1995) (28)
- Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study (2016) (27)
- Oral V2 receptor antagonist (RWJ‐351647) in patients with cirrhosis and ascites: a randomized, double‐blind, placebo‐controlled, single ascending dose study (2006) (26)
- The effect of posture on central blood volume in patients with preascitic cirrhosis on a sodium‐restricted diet (1996) (25)
- Sodium homeostasis with chronic sodium loading in preascitic cirrhosis (2001) (25)
- Augmentin‐induced jaundice (1991) (24)
- Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation (2015) (23)
- Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort (2021) (21)
- Hyperinsulinemia in preascitic cirrhosis: Effects on systemic and renal hemodynamics, sodium homeostasis, forearm blood flow, and sympathetic nervous activity (1996) (21)
- Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), on recurrence of ascites after large volume paracentesis (2006) (21)
- 42 Results of a one-year international phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B (2004) (20)
- An update on the pathogenesis and clinical management of cirrhosis with refractory ascites (2018) (20)
- Refractory Ascites in Liver Cirrhosis (2019) (20)
- Improvement in Quality of Life and Decrease in Large‐Volume Paracentesis Requirements With the Automated Low‐Flow Ascites Pump (2020) (20)
- The mechanism of improved sodium homeostasis of low‐dose losartan in preascitic cirrhosis (2002) (19)
- Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis (2021) (18)
- Phase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Results (2005) (18)
- Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation (1993) (18)
- Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. (1994) (18)
- Percutaneous Ethanol Injection of Unresectable Medium-to-Large-Sized Hepatomas Using a Multipronged Needle: Efficacy and Safety (2007) (17)
- 102 EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY (2009) (17)
- Renal diseases and the liver. (2011) (17)
- Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. (2019) (17)
- Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience (2017) (17)
- Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome (2019) (16)
- Portopulmonary hypertension: an increasingly important complication of cirrhosis. (2003) (16)
- International Ascites Club Sepsis in cirrhosis: report on the 7th meeting of the (2006) (15)
- Radiofrequency ablation of malignant hepatic neoplasms. (2002) (15)
- Cirrhotic cardiomyopathy: does it contribute to chronic fatigue and decreased health-related quality of life in cirrhosis? (2000) (15)
- [90] LONG-TERM IMPROVEMENT OF SERUM SODIUM BY THE V-RECEPTOR ANTAGONIST SATAVAPTAN IN PATIENTS WITH CIRRHOSIS AND HYPONATRAEMIA (2007) (15)
- Liver and kidney diseases. (2002) (15)
- Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. (2015) (15)
- REVIEW: The controversy over the pathophysiology of ascites formation in cirrhosis (1997) (15)
- Ascites and Hepatorenal Syndrome. (2019) (14)
- Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center (2006) (14)
- Intravenous albumin with diuretics: protean lessons to be learnt? (1999) (13)
- Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis (2019) (13)
- Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. (2004) (13)
- The natural history and management of hepatorenal disorders: from pre-ascites to hepatorenal syndrome. (2003) (13)
- Calcium-dependent diuretic system in preascitic liver cirrhosis. (2010) (13)
- The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis. (1995) (12)
- Renal Dysfunction After Liver Transplantation: Effect of Donor Type (2020) (12)
- Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax (2020) (12)
- Epidemiology, predictors and outcomes of multi drug resistant (MDR) bacterial infections in patients with cirrhosis across the world : final results of the 'Global study' (2018) (12)
- Variations in albumin use in patients with cirrhosis: An AASLD members survey (2015) (12)
- Portopulmonary hypertension in cirrhosis: the pathogenetic challenge. (2005) (11)
- Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges? (2005) (11)
- Diagnosing and treating renal disease in cirrhotic patients. (2016) (11)
- COVID‐19 and Liver Cirrhosis: Focus on the Nonclassical Renin‐Angiotensin System and Implications for Therapy (2021) (10)
- Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. (2020) (10)
- Is there a cirrhotic cardiomyopathy (2000) (10)
- Utility of shear‐wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers (2018) (10)
- Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C) (2019) (10)
- Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis (2014) (10)
- Miscellaneous indications for transjugular intrahepatic portosystemic stent-shunt (2006) (10)
- Medical management of ascites (2011) (9)
- Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acute‐on‐Chronic Liver Failure (2019) (9)
- Hepatorenal syndrome: Current management (2008) (9)
- Natriuretic and aquaretic effects of intravenously infused calcium in preascitic human cirrhosis: physiopathological and clinical implications (2007) (9)
- Un‐precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites (2018) (9)
- Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure (2022) (9)
- Peritoneovenous shunting in cirrhosis: its role in the management of refractory ascites in the 1990s. (1995) (9)
- Treatment of Oesophageal Varices in Liver Cirrhosis (2018) (9)
- Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks (2017) (9)
- Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience (2020) (8)
- Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. (1999) (8)
- Effects of sodium status on the venous response to noradrenaline infusion in pre-ascitic cirrhosis. (1995) (8)
- Acute kidney injury: prediction, prognostication and optimisation for liver transplant (2020) (8)
- Transjugular Intrahepatic Portosystemic Stent Shunt for Hepatorenal Syndrome and Ascites (1998) (8)
- The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis. (1995) (8)
- The pathophysiologic basis for the treatment of cirrhotic ascites. (2001) (8)
- Progression of Stage 2 and 3 Acute Kidney Injury in Patients with Decompensated Cirrhosis and Ascites. (2020) (8)
- Hepatorenal syndrome: do the vasoconstrictors work? (2011) (7)
- The impact of acute kidney injury in cirrhosis: does definition matter? (2013) (7)
- Transjugular intrahepatic portosystemic shunt: Is it the ultimate solution for refractory ascites? (1995) (7)
- The Negative Prognostic Impact of a First Ever Episode of Spontaneous Bacterial Peritonitis in Cirrhosis and Ascites (2015) (7)
- The management of cirrhotic ascites. (2002) (7)
- Definition and Diagnosis of Acute Kidney Injury in Cirrhosis (2015) (7)
- The Prediction of In‐Hospital Mortality in Decompensated Cirrhosis with Acute‐on‐Chronic Liver Failure (2021) (7)
- Assessment of central blook volume in cirrhosis by radionusclide angiography: What does it really mean? (1994) (6)
- Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. (2020) (6)
- P0198 : Percentage change in serum creatinine (SCr) is a sensitive indicator of therapeutic response to terlipressin in hepatorenal syndrome type 1 (HRS-1) (2015) (6)
- Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multi-center Inpatient Cirrhosis Cohort. (2022) (6)
- Interim Results of a Double-blind, Randomized Phase 2 Study of the Safety of Tenofovir Disoproxil Fumarate, Emtricitabine plus Tenofovir Disoproxil Fumarate ,and Entecavir in the treatment of chronic hepatitis B subjects with Decompensated liver disease (2009) (6)
- Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis (2019) (6)
- 439 Improving antiviral therapy in chronic hepatitis B: Maximal viral suppression at week 24 correlates with better clinical efficacy at one year (2004) (6)
- Author Correction: Hepatorenal syndrome (2018) (6)
- The effect of varying sodium intake on blood volume, forearm blood flow and vascular responsiveness to sympathetic stimulation in pre-ascitic cirrhosis. (1996) (6)
- Epidemiology, predictors and outcomes of multi drug resistant bacterial infections in patients with cirrhosis across the world. Final results of the “Global study” (2018) (5)
- Natriuretic peptides: are these new links in the hepatorenal connections? (1997) (5)
- The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: A multi-center randomized placebo controlled trial (2000) (5)
- The effect of single oral low‐dose losartan on posture‐related sodium handling in post‐TIPS ascites‐free cirrhosis (2006) (5)
- [Diastolic dysfunction in liver cirrhosis]. (2005) (5)
- The patient with renal insufficiency. (1996) (5)
- Interferon therapy prevents hepatocellular carcinoma in some patients with chronic HCV: the role of fibrosis. (2000) (5)
- Treatment to Improve Acute Kidney Injury in Cirrhosis (2015) (5)
- Effects of insulin on renal function, sympathetic nervous activity and forearm blood flow in normal human subjects. (1997) (5)
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study (2018) (4)
- Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever (2019) (4)
- Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis (2022) (4)
- Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study (2022) (4)
- P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patients (2015) (4)
- Herbal remedies for the liver: myths, proofs, and treatments. (1999) (4)
- Stopping the unstoppable? (2000) (4)
- An advance in the treatment of portal hypertension? (2000) (4)
- Double-blind, placebo-controlled study of satavaptan in the management of recurrent ascites: the spare-1 study (2009) (4)
- Latest Treatment of Acute Kidney Injury in Cirrhosis (2020) (4)
- A180 IMPROVED RENAL LABORATORY PARAMETERS IN CHB PATIENTS TREATED WITH TAF COMPARED WITH TDF (2018) (4)
- Hepatoportal thromboses are no longer idiopathic. (2000) (4)
- Porto-pulmonary hypertension in decompensated cirrhosis and refractory ascites (2001) (4)
- Nifedipine: its effects on renal hemodynamics and sodium homeostasis in well-compensated alcoholic cirrhosis. (1994) (4)
- Corrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974] (2015) (4)
- Does Repeated Paracentesis Prevent Spontaneous Bacterial Peritonitis? (1999) (4)
- Unexpected renal and liver failure. (2010) (4)
- Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study (2016) (4)
- 653 IS TYPE 1 HEPATORENAL SYNDROME REVERSIBLE AFTER LIVER TRANSPLANTATION (2012) (3)
- Acute renal dysfunction in liver cirrhosis. (2013) (3)
- Therapy for hepatorenal syndrome. (1998) (3)
- Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival (2016) (3)
- SP222REDUCTION IN ACUTE KIDNEY INJURY (AKI) STAGE IS A STRONG PREDICTOR OF SURVIVAL IN PATIENTS WITH HEPATORENAL SYNDROME TYPE-1 (HRS-1) TREATED WITH TERLIPRESSIN PLUS ALBUMIN OR ALBUMIN ALONE (2015) (3)
- Excess nitric oxide in preascites: another piece in the puzzle (2002) (3)
- SAT-141-The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start? (2019) (3)
- Effect of insulin on the venoconstrictive response to norepinephrine in normal human subjects: the influence of sodium status. (1994) (3)
- 575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic Patients (2015) (3)
- 226 LONG-TERM ANTIBIOTIC AND PROTON-PUMP INHIBITOR USE ARE STRONG PREDICTORS OF RECURRENT INFECTIONS IN CIRRHOSIS: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD (2013) (3)
- Assessment of central blood volume in cirrhosis by radionuclide angiography (1994) (3)
- Insurance Status but Not Race/Ethnicity are Associated with Outcomes in a Large Hospitalized Cohort of Patients with Cirrhosis. (2020) (3)
- Ascites and portal-systemic encephalopathy as complications of cirrhosis (1993) (3)
- Chapter 22 – The Liver in Heart Failure (2004) (2)
- Excess nitric oxide in preascites: another piece in the puzzle. (2002) (2)
- Terlipressin and albumin for HRS: an advance in therapy? (2003) (2)
- Prognosis of hospitalized patients with cirrhosis and acute kidney disease (2022) (2)
- Pathophysiology and treatment of hepatorenal syndrome. (1998) (2)
- Role Of Oral Health, Frailty and Minimal Hepatic Encephalopathy In The Risk Of Hospitalization: A Prospective Multi-Center Cohort Of Outpatients with Cirrhosis. (2022) (2)
- Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections. Results from the ICA Global Study (2018) (2)
- IN-HOSPITAL MORTALITY IN CIRRHOSIS IS RELATED TO NOSOCOMIAL INFECTIONS INDEPENDENT OF MELD SCORE: THE NORTH AMERICAN CONSORTIUM FOR THE STUDY OF END-STAGE LIVER DISEASE (NACSELD) STUDY (2012) (2)
- Does Losartan Work After All? (2003) (2)
- P943 DIFFERENCES IN CREATININE BETWEEN GENDERS COULD DISADVANTAGE INFECTED CIRRHOTIC WOMEN: THE NACSELD EXPERIENCE (2014) (2)
- Portal hypertensive gastropathy. (2007) (2)
- A marker for predictions of HCC recurrence postresection? (2002) (2)
- AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients with Cirrhosis: Expert Review. (2022) (2)
- Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies (2020) (2)
- 857 SATAVAPTAN EFFICACY AND SAFETY IN RECURRENT ASCITES WITHOUT CONCOMITANT DIURETICS: THE SPARE-2 STUDY (2010) (2)
- 368 REDUCED BONE MINERAL DENSITY DERIVED FROM DUAL X-RAY ABSORPTIOMETRY ASSESSMENTS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) (2011) (2)
- Does losartan work after all (2003) (2)
- SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation (2019) (1)
- 201 The effect of transjugular intrahepatic portosystemic stent shunt (TIPS) on cardiac function and structure in cirrhotic patients with refractory ascites (2004) (1)
- Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know. (2023) (1)
- Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival (2016) (1)
- P0199 : Acute kidney injury in cirrhosis: Baseline serum creatinine predicts patient outcomes (2015) (1)
- Diagnosis and management of acute kidney injury in patients with cirrhosis : Revised consensus recommendations of the International Club of Ascites q (2015) (1)
- Blocking the bleeding way. (1998) (1)
- Transplantation for hepatitis C: good news and bad news. (1999) (1)
- Hepatorenal failure. (2000) (1)
- A73 PHARYNGEAL VARICES AS A COMPLICATION OF PORTAL HYPERTENSION: A CASE SERIES (2020) (1)
- The cardiopulmonary effects of transjugular intrahepatic portosystemic stent shunt (TIPS) in cirrhotic patients with refractory ascites. (2002) (1)
- P0119 : Validation Of The NACSELD Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) score in an independent multicenter cohort (2015) (1)
- Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic Patients (2017) (1)
- Treatment of hepatoportal venous thrombosis: the role of anticoagulation. (2001) (1)
- Regional variations in the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis and bacterial infections (2018) (1)
- SBP and the pathogenesis of renal failure-the hidden triangle. (2004) (1)
- Reply to JHEPAT-D-21-00702 and JHEPAT-D-21-00793. (2021) (1)
- Acute-on-chronic liver failure as defined by the European (EASL-CLIF) versus North American (NACSELD) diagnostic criteria in their prediction of short-term prognosis in patients with decompensated cirrhosis admitted into hospital (2020) (1)
- Management of Ascites (2019) (1)
- Mo1892 Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes (2015) (1)
- The role of liver biopsy in the management of patients with liver disease. (2003) (1)
- Complications of Cirrhosis: Ascites and Spontaneous Bacterial Peritonitis (2004) (1)
- The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites: Ochs A, Rossle M, Haag K, Hauenstein K-H, Deibert P, Siegerstetter V, Hounker M, et al. N Engl J Med 1995; 332: 1192–1197 (1995) (1)
- Cirrhosis; Acute Kidney Injury (2020) (1)
- 543 In-Hospital Mortality in Cirrhosis is Related to Nosocomial Infections Independent of MELD Score:the North American Consortium for the Study of End-Stage Liver Disease (Nacseld) Study (2012) (1)
- Management of ascites and hepatorenal syndrome (2009) (1)
- Vascular Liver Disease: Mechanisms and Management (2012) (1)
- Verified Hepatorenal Syndrome Reversal As A Robust Multi-Component Primary End Point: The CONFIRM Study Trial Design (2019) (1)
- Mo1027 Differences in Creatinine Between Genders Could Disadvantage Infected Cirrhotic Women: The Nacseld Experience (2014) (1)
- Management of bleeding stomal varices (2014) (1)
- In experimental preascitic liver cirrhosis calcium-dependent diuretic systems are downregulated, but may be normalized by specific metabolic and pharmacologic stimuli (2007) (1)
- SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites (2019) (1)
- Historical Aspects of Ascites and the Hepatorenal Syndrome (2021) (0)
- Transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis of individual patient data (2007) (0)
- Cardiac changes in pediatric liver transplant recipients: are they truly irreversible? (2016) (0)
- Albumin Use and Acute Kidney Injury in a Large Real-World Analysis of Cirrhotic Inpatients (2017) (0)
- Reply (to LTE HEP‐18‐1401) (2018) (0)
- G14 : Systemic inflammatory response syndrome (SIRS) is a major determinant of treatment response to terlipressin for hepatorenal syndrome type 1 (HRS-1) (2015) (0)
- Functional capacity in cirrhosis is predicted by additive impact of covert hepatic encephalopathy and frailty in a multi-center outpatient cohort (2021) (0)
- Repeated episodes of acute kidney injury on the transplant waiting list: Impact on post-liver transplantation renal and patient outcomes (2018) (0)
- Let's Have Some Clarity on Academic Parity. (2022) (0)
- Clinical Challenge New Challenge of Hepatorenal Syndrome : Prevention and Treatment (2001) (0)
- In-Hospital Mortality Related to Hepatic Encephalopathy is Independent of Acute-On-Chronic Liver Failure and Varies Significantly across North America: Nacseld Experience (2016) (0)
- Tu1649 Predicting Mortality After Discharge From Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score (2016) (0)
- 573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with Decompensation (2019) (0)
- Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR‐ABL negative myeloproliferative neoplasms (2023) (0)
- 4:21 PM Abstract No. 70 Technical considerations and outcomes from the MOSAIC study: a multicenter, open-label prospective study of the Alfapump system used for management of refractory ascites (2018) (0)
- The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome. (2023) (0)
- Portal hypotensive action of type-I calcimimetic compounds in rats with CCl4-induced ascitic liver cirrhosis (2009) (0)
- 256: PRIOR PERIODONITIS AND PATIENT-REPORTED OUTCOMES PREDICT THE RISK OF 3-MONTH HOSPITALIZATION IN A MULTI-CENTER CIRRHOSIS COHORT (2022) (0)
- Dose-Dependent Effects of Oral Function in Alcoholic Cirrhosis Misoprostol on Renal (1994) (0)
- Chronic Kidney Disease in Patients with Liver Cirrhosis, Phenotypic Precision Matters. (2019) (0)
- Reply (2020) (0)
- Reply (2018) (0)
- TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT FOR REFRACTORY ASCITES : SHUNT DIAMETER-OPTIMIZING RISKS AND BENEFITS. AUTHORS' REPLY (1997) (0)
- P10: Atypical Presentation of Childhood Leukaemia (2010) (0)
- P905 THE RISK OF DELISTING OR DEATH IN LIVER TRANSPLANT CANDIDATES INCREASES FOLLOWING INFECTIONS: RESULTS FROM THE NACSELD CONSORTIUM (2014) (0)
- More therapy for hepatorenal syndrome. (1999) (0)
- Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score (2016) (0)
- Regarding the letter in response to our review: the management of cirrhotic ascites. (2002) (0)
- REPLY: (2021) (0)
- The Cardiorenal Connection: Is Cardiac Output the Sole Determinant of Renal Dysfunction in Cirrhosis? (2022) (0)
- Analysis on the status of hepatitis B virus DNA in peripheral blood mononuclear cells of chronic hepatitis B patients (1993) (0)
- Mo1389 - Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The Endurance-5,6 Study (2018) (0)
- 431 SPECIFIC URINARY AND SERUM METABOLITES ON ADMISSION PREDICT THE DEVELOPMENT OF AKI AND NEED FOR DIALYSIS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS (2021) (0)
- IDDF2018-ABS-0067 Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study (2018) (0)
- Management of Portal Hypertension in Patients with Acute-on-Chronic Liver Disease (2023) (0)
- P502 SPONTANEOUS BACTERIAL PERITONITIS AND BACTEREMIA PREDICT MORTALITY IN CIRRHOSIS DESPITE PROPHYLACTIC MEASURES: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD (2014) (0)
- Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis (2018) (0)
- CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease (2022) (0)
- 458 ARTIFICIAL INTELLIGENCE TECHNIQUES DEMONSTRATE BETTER PREDICTION FOR 90-DAY READMISSION AND DEATH IN WOMEN THAN MEN WITH CIRRHOSIS. (2020) (0)
- 83 THE NEW CONSENSUS DEFINITION OF ACUTE KIDNEY INJURY IS VALID IN PREDICTING MORTALITY IN HOSPITALIZED INFECTED CIRRHOTIC PATIENTS: THE NACSELD EXPERIENCE (2013) (0)
- SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort (2019) (0)
- Hepatorenal syndrome: are we doing better? (2004) (0)
- ransjugular Intrahepatic Portosystemic Shunt for Refractory Ascites : Meta-analysis of Individual Patient Data (0)
- Recent advances in clinical practice SEPSIS IN CIRRHOSIS : REPORT ON THE 7 TH MEETING OF THE INTERNATIONAL ASCITES CLUB (2005) (0)
- Determinants of clinical efficacy of empirical antibiotic treatment in patients with cirrhosis and bacterial infections: Results from the ICA global study (2018) (0)
- Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development (2013) (0)
- Sa1640 The Use of Albumin in Decompensated Cirrhosis: Are the Indications Approrpriate and the Desired Outcomes Achieved? (2016) (0)
- Renal Complications of Liver Disease and the Hepatorenal Syndrome (2011) (0)
- 17 – Renal Failure in Cirrhosis (2018) (0)
- Prevention of varices rebleeding: are drugs better after all? (2002) (0)
- Acute Kidney Injury in Cirrhosis (2019) (0)
- Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections : results from the ICA 'Global Study' (2018) (0)
- M1711 Are the Characteristics of Patients with Cirrhosis and Decompensation Changing? a Study Comparing Two Time Periods (2009) (0)
- 195 I.V. infused calcium has marked diuretic and natriuretic effects in pre-ascitic human cirrhosis: Physiopathological and clinical implications (2006) (0)
- Treatment of hepatorenal syndrome (2006) (0)
- Reply (2019) (0)
- Erratum: The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt (2009) (0)
- [250] THE EFFECTS OF TEZOSENTAN, AN ENDOTHELIN RECEPTOR ANTAGONIST, ON RENAL FUNCTION IN PATIENTS WITH CIRRHOSIS COMPLICATED BY ASCITES AND HEPATORENAL SYNDROME (2007) (0)
- Management of hepatorenal syndrome in liver cirrhosis: a recent update (2022) (0)
- [121] IN EXPERIMENTAL PREASCITIC LIVER CIRRHOSIS CALCIUM-DEPENDENT DIURETIC SYSTEMS ARE DOWNREGULATED, BUT MAY BE NORMALIZED BY SPECIFIC METABOLIC AND PHARMACOLOGIC STIMULI (2007) (0)
- Vaptans for Ascites – Chances and Risks (2011) (0)
- Automated low flow ascites pump (alfapump) for refractory ascites: still a long way to travel? Probably not. (2020) (0)
- Recommendations for the Management of Immunosuppression in Patients with Preoperative and Postoperative Renal Dysfunction (2009) (0)
- CHAPTER 8 – Hepatorenal syndrome (2012) (0)
- The Diagnosis of Acute Kidney Injury in Cirrhosis: The Reasonable Cut-off Serum Creatinine Value (2016) (0)
- Lamivudine for hepatitis B: the end of the beginning? (2001) (0)
- Correspondence (2003) (0)
- Hepatorenal syndrome: updates (2023) (0)
- Sympathetic hyperactivity in pre-ascites. (2002) (0)
- Renal dysfunction in cirrhosis, does the baseline renal function matter? (2017) (0)
- EASL Recognition Awardee for 2014: Prof. Tilman Sauerbruch. (2014) (0)
- 856 ANTIBIOTIC PROPHYLAXIS FOLLOWING AN EPISODE OF SPONTANEOUS BACTERIAL PERITONITIS DOES NOT PROTECT AGAINST THE SUBSEQUENT DEVELOPMENT OF RENAL DYSFUNCTION IN DECOMPENSATED CIRRHOSIS (2010) (0)
- Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply. (2021) (0)
- Editorial: terlipressin in patients with ACLF grade 3—too late? Authorsʼ reply (2022) (0)
- Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis Running head : Short-term mortality after discharge from hospital in cirrhosis (2016) (0)
- End-Of-Life Healthcare Costs and Utilization among Patients with End-Stage-Liver-Disease in Ontario: A Population-Based Study (2016) (0)
- Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference-Decompensated cirrhosis: from clinic to transplant. (2019) (0)
- Speckle tracking echocardiography in cirrhosis: is it ready for prime time? (2014) (0)
- Reply to Jindal et al. (2021) (0)
- 185 The effects of losartan, an angiotensin II receptor antagonist, on posture related sodium handling in ascites-free post-tips cirrhotic patients previously treated for refractory ascites (2004) (0)
- 499 - Primary SBP Prophylaxis is Associated with Higher ICU Admission and 30-Day Mortality Compared to Secondary SBP Prophylaxis (2018) (0)
- The optimal dose of concomitant albumin for the treatment of hepatorenal syndrome type 1 - what is it? (2017) (0)
- The ‘Gerstmann's Syndrome’ of transjugular intrahepatic portosystemic shunt: should it be the left or should it be the right (2009) (0)
- SAT-093-Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience (2019) (0)
- Su1527 – Potentially Preventable Readmissions and Complications in Hospitalized Patients with Hepatic Encephalopathy in a Large Multi-Center Cohort (2019) (0)
- Su1678 IMPACT OF RACE AND ETHNICITY ON OUTCOMES IN A MULTI-CENTER NORTH AMERICAN COHORT OF INPATIENTS WITH CIRRHOSIS (2020) (0)
- Reply: (2018) (0)
- Acute on chronic liver failure-comparison of patients identified by the European association for the study of the liver and the North American consortium for study of end-stage liver diseases (2018) (0)
- Tu1722 COMPARISON OF EUROPEAN (EASL-CLIF) WITH THE NORTH AMERICAN (NACSELD) DIAGNOSIS CRITERIA FOR ACUTE-ON-CHRONIC LIVER FAILURE IN PREDICTION OF SHORT-TERM PROGNOSIS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS (2020) (0)
- Hepatorenal syndrome: Is it truly the end of the road? (2002) (0)
- Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and Ascites (2019) (0)
- Prior or on-treatment infection does not affect response to treatment or survival in patients with hepatorenal syndrome type 1 (2018) (0)
- A71 MESOCAVAL SHUNT EMBOLIZATION AS A TREATMENT FOR MEDICALLY REFRACTORY HEPATIC ENCEPHALOPATHY IN A PATIENT WITH NON-DECOMPENSATED CIRRHOSIS (2020) (0)
- 591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic Patients (2015) (0)
- Sa1570 – Underutilization of Hospice in Inpatients with Cirrhosis: the Nacseld Experience (2019) (0)
- Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis (2022) (0)
- Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney disease (2020) (0)
- Management of refractory ascites (2022) (0)
- 82: SERUM METABOLITES ON ADMISSION ASSOCIATE WITH OCCURRENCE OF NOSOCOMIAL INFECTIONS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS (2022) (0)
- Sa1456: SBP VERSUS NON-SBP BACTERIAL INFECTIONS AT ADMISSION HAVE COMPARABLE OUTCOMES IN A MULTI-CENTER COHORT OF INPATIENTS WITH CIRRHOSIS (2022) (0)
- Hepatorenal syndrome and acute kidney injury (2015) (0)
- Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study (2022) (0)
- 765 TYPE-I CALCIMIMETIC COMPOUNDS EXERT PORTAL HYPOTENSIVE EFFECTS IN RATS WITH CCL4-INDUCED ASCITIC LIVER CIRRHOSIS: A NEW THERAPEUTIC OPTION? (2009) (0)
- 626 CIRCULATORY DYSFUNCTION AFTER LARGE VOLUME PARACENTESIS IS NOT ASSOCIATED WITH RENAL IMPAIRMENT OR INCREASED MORTALITY IN PATIENTS WITH CIRRHOSIS AND ASCITES (2012) (0)
- GUIDELINE TO PRACTICE: ACUTE ON CHRONIC LIVER FAILURE. (2022) (0)
- Su1513 In-Hospital Mortality Related to Hepatic Encephalopathy Is Independent of ACLF and Varies Significantly Across North America: NACSELD Experience (2016) (0)
This paper list is powered by the following services:
Other Resources About Florence Wong
What Schools Are Affiliated With Florence Wong?
Florence Wong is affiliated with the following schools:
